Analystreport

CRISPR Therapeutics AG (NASDAQ: CRSP) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $66.00 to $57.00. They now have a "neutral" rating on the stock.

CRISPR Therapeutics AG - Common Shares  (CRSP) 
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm Check Earnings Report
US:NASDAQ Investor Relations: nasdaq.com/symbol/crsp/real-time